Exigent Pharmaceuticals exigentpharmaceuticals.com


Public lists: Pharma Startups (4743)

Exigent Pharmaceuticals is a new biopharmaceutical company focused on the development and commercialization of anti-infectives. Exigent is currently developing new pharmaceuticals to treat drug-resistant bacterial infections, using its technology platform.

Exigent Pharmaceuticals is a new biopharmaceutical company focused on the development and commercialization of anti-infectives. Exigent is currently developing new pharmaceuticals to treat drug-resistant bacterial infections, using its technology pl...Show all

Company (Alive / Active)

Phone: 919-386-9694

Fax: N/A

2530 Meridian Parkway
Suite 200
Durham, 27713
North Carolina, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Exigent Pharmaceuticals $0M Apr 19, 2019
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Exigent Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Innoviva

Brisbane, California, United States
IPO / Went publicInnoviva, formerly known as Theravance, is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible...Show allLogin to see details

Inhibitex

Alpharetta, Georgia, United States
IPO / Went publicInhibitex is a biopharmaceutical company that is pursuing the development and commercialization of products for the infectious disease market. Inhibitex has a proprietary technology platform that utilizes antibodies to fight bacterial infections.Login to see details
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)